UB-221
UB-221 is a humanized IgG1 monoclonal antibody inhibitor targeting IgE. UB-221 significantly decreases IgE synthesis by stabilization of membrane-bound CD23 on B lymphocytes and inhibits FcԑRI-mediated basophil activation and degranulation. UB-221 reduces IgE level in cynomolgus macaques and human IgE (ε, κ) -transgenic (hIGHE-knockin) mice. UB-221 can be used for asthma and chronic spontaneous urticaria (CSU) research[1].
Product Specifications
CAS Number
2755114-30-6
UNSPSC
12352203
Target
Others
Related Pathways
Others
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
References & Citations
[1]Kuo BS, et al. IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms. J Clin Invest. 2022 Aug 1;132 (15) :e157765. |[2]Casale TB. Novel biologics for treatment of chronic spontaneous urticaria. J Allergy Clin Immunol. 2022 Dec;150 (6) :1256-1259.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC470253-500 1x 500 µL
Cytokeratin, LMW (AE-1), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680253-100 1x 100 µL
Cytokeratin, LMW (AE-1), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC681429-100 1x 100 µL
E-Cadherin / CD324 (Intercellular Junction Marker) (4A2), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC401563-500 1x 500 µL
Filaggrin (Keratinocyte Differentiation Marker) (FLG/1563), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC471012-100 1x 100 µL
S100B (S100B/1012), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details